RBC: 'we expect to see a negative impact to VRDN's shares', Shares 24% Today
April 6, 2026 11:45 AM
RBC Capital analyst Lisa Walter reiterated an Outperform rating and $42.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
